UGT1A1, siRNA

GNT1; UGT1; UDP-glucuronosyltransferase 1-1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; Bilirubin-specific UDPGT isozyme 1; hUG-BR1; UDP-glucuronosyltransferase 1-A; UGT-1A; UGT1A; UDP-glucuronosyltransferase 1A1

For Research Use Only. Not for use in diagnostic procedures.

Synthetic

UGT1A1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

> 97%

Lyophilized powder

Shipped at 4 degree C. Store at -20 degree C for one year.

siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.

Small volumes of UGT1A1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

siRNA to inhibit UGT1A1 expression using RNA interference

RNA Interference (RNAi)

49,368 Da

UDP glucuronosyltransferase 1 family, polypeptide A1

UDP-glucuronosyltransferase 1-1

UDP-glucuronosyltransferase 1-1

GNT1; UGT1; UDPGT 1-1; UGT1*1; UGT1-01; UGT1.1; hUG-BR1; UGT-1A; UGT1A  [Similar Products]

UD11_HUMAN

This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate , and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome. [provided by RefSeq, Jul 2008]

UGT1A1: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX- alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4- methylumbelliferone, 1-naphthol, paranitrophenol, scopoletin, and umbelliferone. Part a large chaperone multiprotein complex comprising DNAJB11, HSP90B1, HSPA5, HYOU, PDIA2, PDIA4, PDIA6, PPIB, SDF2L1, UGT1A1 and very small amounts of ERP29, but not, or at very low levels, CALR nor CANX. Expressed in liver. Not expressed in skin or kidney. Belongs to the UDP-glycosyltransferase family. 1 isoforms of the human protein are produced by alternative splicing.

Protein type: Lipid Metabolism - androgen and estrogen; Membrane protein, integral; Cofactor and Vitamin Metabolism - porphyrin and chlorophyll; Xenobiotic Metabolism - drug metabolism - cytochrome P450; Carbohydrate Metabolism - starch and sucrose; Carbohydrate Metabolism - pentose and glucuronate interconversions; Xenobiotic Metabolism - drug metabolism - other enzymes; Carbohydrate Metabolism - ascorbate and aldarate; Cofactor and Vitamin Metabolism - retinol; Transferase; EC 2.4.1.17; Xenobiotic Metabolism - metabolism by cytochrome P450

Chromosomal Location of Human Ortholog: 2q37

Cellular Component: endoplasmic reticulum membrane; endoplasmic reticulum; integral to plasma membrane

Molecular Function: enzyme inhibitor activity; retinoic acid binding; enzyme binding; protein homodimerization activity; glucuronosyltransferase activity; protein heterodimerization activity; steroid binding

Biological Process: response to drug; steroid metabolic process; estrogen metabolic process; organ regeneration; negative regulation of steroid metabolic process; response to lipopolysaccharide; negative regulation of fatty acid metabolic process; liver development; cellular response to hormone stimulus; response to starvation; negative regulation of transferase activity; flavonoid biosynthetic process; bilirubin conjugation; heme catabolic process; xenobiotic metabolic process; digestion; negative regulation of catalytic activity; porphyrin metabolic process; flavone metabolic process; acute-phase response; retinoic acid metabolic process; heterocycle metabolic process; drug metabolic process; response to nutrient

Disease: Gilbert Syndrome; Crigler-najjar Syndrome, Type I; Bilirubin, Serum Level Of, Quantitative Trait Locus 1; Crigler-najjar Syndrome, Type Ii; Hyperbilirubinemia, Transient Familial Neonatal

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.